Collaboration across the Øresund – Camurus enters Danish licensing agreement

Together, the companies will develop a long‑acting treatment option for hypoparathyroidism, a rare hormonal disorder in which the body produces too little parathyroid hormone (PTH). This in turn leads to an imbalance of calcium and phosphate in the body, affecting organs such as the kidneys, bones, and nervous system.